EU safety committee reviews Deanxit and allergic reactions to some immunoglobulin batches
The European Medicines Agency's safety committee, the PRAC, met from 26 to 29 October 2026 and has started re-evaluating Deanxit, a combined depression and anxiety medicine. The review follows reports of serious movement and memory problems, some lasting after patients stopped treatment. The committee has also begun looking at a rise in allergic reactions linked to certain batches of immunoglobulin medicines, which are blood-derived antibody treatments.
This summary was generated by AI; the official source prevails.
What does it mean?
Deanxit, a medicine used for depression and anxiety, is now under a fresh European safety review after reports of serious side effects. If you take it, these reports matter for what doctors may decide next. The review is at an early stage, so no final decision has been made yet.
Who is affected?
Patients taking Deanxit and the doctors who prescribe it, plus people receiving certain immunoglobulin treatments.